Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone

Acta Anaesthesiologica Scandinavica

Volumn 41, Issue 2, 1997, Pages 309-312

  Takala, A ^a,b   Kaasalainen, V ^b   Seppala T ^c   Kalso, E ^a   Olkkola, K T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

analgesics, route of administration: intravenous, intranasal; analgesics: oxycodone; analgesics: pharmacokinetics

Indexed keywords

OXYCODONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE;

EID: 0031045713     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.1997.tb04684.x     Document Type: Article

References (18)

1. Kalso E, Vainio A. Morphine and oxcodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990: 47: 631-646.
2. Kalso E, Pöyhiä R, Onnela P, Linko K, Tigerstedt I, Tammisto T. Oxycodone and morphine in postoperative pain. Acta Anaesthesiol Scand 1991: 35: 642-646.
3. Leow KP, Smith MT, Watt JA, Williams BE, Cramond T. Comparative oxycodone pharmacokinetics in humans after intravenous, oral and rectal administration. Ther Drug Monit 1992a: 14: 479-484.
4. Leow KP, Smith MT, Williams BE, Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992b: 52: 487-495.
5. Pöyhiä R, Olkkola KT, Seppälä T, Kalso E. The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmacol 1991: 32: 516-518.
6. Pöyhiä R, Seppälä T, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992: 33: 617-621.
7. Parr GD. Nasal delivery of drugs. Pharm Int 1983: 4: 202-205.
8. Pontiroli AE, Caldera A, Pozza G. Intranasal drug delivery. Clin Pharmacokin 1989: 17: 299-307.
9. Striebel HW, Pommerening J, Rieger A. Intranasal fentanyl titration for postoperative pain management in an unselected population. Anaesthesia 1993: 48: 757-757.
10. Abboud TK, Zhu J, Gangolly J, Longhitano M, Swart F, Makar A, et al. Transnasal butorphanol: a new method for pain relief in post-cesarean section pain. Acta Anaesthesiol Scand 1991: 35: 14-18.
11. Henderson JM, Brodsky DA, Fisher DM, Brett CM, Hertzka RE. Pre-induction of anesthesia in pediatric patients with nasally administered sufentanil. Anesthesiology 1988: 68: 671-675.
12. Eriksen J, Jensen N-H, Kamp-Jensen M, Bjarnø H, Friis P, Brewster D. The systemic bioavailability of buprenorphine administered by nasal spray. J Pharm Pharmacol 1989: 41: 803-805.
13. Helmers JHJH, Noorduin H, Van Peer A, Van Leeuwen L, Zuurmond WWA. Comparison of intravenous and intranasal sufentanil absorption and sedation. Can J Anaesth 1989: 36: 494-497.
14. Hardy JC, Lee SW, Wilson CG. Intranasal drug delivery by spray and drops. J Pharm Pharmacol 1985: 37: 294-297.
15. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edition. New York: Marcel Dekker, Inc., 1982.
16. Foley KF. The treatment of cancer pain. N Engl J Med 1989: 313: 84-95.
17. Cool WM, Kurtz NM, Chu G. Transnasal delivery of systemic drugs. Adv Pain Res Ther 1990: 14: 241-258.
18. Shyu WC, Pittman KA, Robinson D, Barbhaiya RH. Multiple-dose phase I study of transnasal butorphanol. Clin Pharmacol Ther 1993: 54: 34-41.